Načítá se...
Vesomni improves the quality of life in men with lower urinary tract symptoms in routine clinical practice in Europe
AIM: To evaluate the impact of Vesomni/Urizia/Volutsa, a fixed‐dose combination tablet containing 6 mg solifenacin (antimuscarinic) and 0.4 mg tamsulosin (α‐blocker), on health‐related quality of life (HRQoL) and treatment satisfaction in men with lower urinary tract symptoms (LUTS) associated with...
Uloženo v:
| Vydáno v: | Neurourol Urodyn |
|---|---|
| Hlavní autoři: | , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley and Sons Inc.
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6916269/ https://ncbi.nlm.nih.gov/pubmed/30801782 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/nau.23944 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|